CHEPLAPHARM Arzneimittel GmbH has successfully gained a foothold in the US American institutional bond market.

CHEPLAPHARM Arzneimittel GmbH Announces Pricing of €575 Million 4.375% Senior Secured Notes due 2028 $500 Million 5.500% Senior Secured Notes due 2028

CHEPLARPHARM announces that it is in advanced negotiations to acquire additional marketing authorizations and intellectual properties for additional territory not yet owned by us for one of our…

CHEPLAPHARM Arzneimittel GmbH Announces Offering of €1,000,000,000 (equivalent) Senior Secured Notes due 2028

CHEPLARPHARM announces the acquisition of two product portfolios from LeoPharma and Takeda

Greifswald, 06/22/2020

Greifswald, 06/22/2020

Greifswald, 05/15/2020 – The family-owned pharmaceutical company CHEPLAPHARM Arzneimittel GmbH got honoured with the highly coveted 'Axia Best Managed Companies Award' for the second time in a row.…

Cheplapharm Arzneimittel GmbH - Quarterly Update Call Q4 / FY 2019 | Wednesday, 08 April 2020, 10:30 BST | 11:30 CEST

Due to the COVID-19 situation, CHEPLAPHARM Arzneimittel GmbH is closely monitoring the potential impact on the various Supply Chains and is committed to keep a transparent approach to all involved …